المؤلفون: Sahhar J., Conron M., Littlejohn G.

مصطلحات الفهرس: dose response, early diagnosis, fever/si [Side Effect], fibrosing alveolitis/di [Diagnosis], fibrosing alveolitis/dt [Drug Therapy], hematuria/si [Side Effect], hemorrhagic cystitis/si [Side Effect], high resolution computer tomography, human, pneumonia/si [Side Effect], infection/si [Side Effect], infertility/si [Side Effect], kidney disease/co [Complication], kidney disease/si [Side Effect], leukopenia/si [Side Effect], lung biopsy, lung function test, lung lavage, lung scintiscanning, maximum permissible dose, myelodysplasia/si [Side Effect], nausea/si [Side Effect], nephrotoxicity/si [Side Effect], osteoporosis/co [Complication], pathology, patient monitoring, pneumocystosis/dt [Drug Therapy], pneumocystosis/et [Etiology], pneumocystosis/pc [Prevention], thorax radiography, vomiting/si [Side Effect], autoantibody/ec [Endogenous Compound], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/iv [Intravenous Drug Administration], cotrimoxazole/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/do [Drug Dose], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], interleukin 8/ec [Endogenous Compound], mesna/ae [Adverse Drug Reaction], mesna/cb [Drug Combination], mesna/dt [Drug Therapy], methotrexate/ae [Adverse Drug Reaction], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], methotrexate/iv [Intravenous Drug Administration], penicillamine/ae [Adverse Drug Reaction], penicillamine/ad [Drug Administration], penicillamine/cb [Drug Combination], penicillamine/dt [Drug Therapy], penicillamine/iv [Intravenous Drug Administration], penicillamine/po [Oral Drug Administration], pentetate technetium tc 99m, placebo, prednisolone/ae [Adverse Drug Reaction], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], tumor necrosis factor alpha/ec [Endogenous Compound], unclassified drug, dna topoisomerase antibody/ec [Endogenous Compound], scl 70 antibody/ec [Endogenous Compound], immunosuppressive treatment, priority journal, review, screening, systemic sclerosis/dt [Drug Therapy], algorithm, alopecia/si [Side Effect], bladder cancer/si [Side Effect], bladder disease/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cause of death, clinical feature, clinical trial, cytopenia/si [Side Effect], disease marker, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32494
Click here for full text options
LibKey Link

المؤلفون: Sahhar J., Conron M., Littlejohn G.

مصطلحات الفهرس: dose response, early diagnosis, fever/si [Side Effect], fibrosing alveolitis/di [Diagnosis], fibrosing alveolitis/dt [Drug Therapy], hematuria/si [Side Effect], hemorrhagic cystitis/si [Side Effect], high resolution computer tomography, human, pneumonia/si [Side Effect], infection/si [Side Effect], infertility/si [Side Effect], kidney disease/co [Complication], kidney disease/si [Side Effect], leukopenia/si [Side Effect], lung biopsy, lung function test, lung lavage, lung scintiscanning, maximum permissible dose, myelodysplasia/si [Side Effect], nausea/si [Side Effect], nephrotoxicity/si [Side Effect], osteoporosis/co [Complication], pathology, patient monitoring, pneumocystosis/dt [Drug Therapy], pneumocystosis/et [Etiology], pneumocystosis/pc [Prevention], thorax radiography, vomiting/si [Side Effect], autoantibody/ec [Endogenous Compound], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/iv [Intravenous Drug Administration], cotrimoxazole/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/do [Drug Dose], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], interleukin 8/ec [Endogenous Compound], mesna/ae [Adverse Drug Reaction], mesna/cb [Drug Combination], mesna/dt [Drug Therapy], methotrexate/ae [Adverse Drug Reaction], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], methotrexate/iv [Intravenous Drug Administration], penicillamine/ae [Adverse Drug Reaction], penicillamine/ad [Drug Administration], penicillamine/cb [Drug Combination], penicillamine/dt [Drug Therapy], penicillamine/iv [Intravenous Drug Administration], penicillamine/po [Oral Drug Administration], pentetate technetium tc 99m, placebo, prednisolone/ae [Adverse Drug Reaction], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], tumor necrosis factor alpha/ec [Endogenous Compound], unclassified drug, dna topoisomerase antibody/ec [Endogenous Compound], scl 70 antibody/ec [Endogenous Compound], immunosuppressive treatment, priority journal, review, screening, systemic sclerosis/dt [Drug Therapy], algorithm, alopecia/si [Side Effect], bladder cancer/si [Side Effect], bladder disease/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cause of death, clinical feature, clinical trial, cytopenia/si [Side Effect], disease marker, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32494
LibKey Link

المؤلفون: Spernat D., Kourambas J.

مصطلحات الفهرس: kidney colic/dt [Drug Therapy], kidney colic/th [Therapy], low fat diet, mental health, nephrotic syndrome/si [Side Effect], pancytopenia/si [Side Effect], priority journal, prophylaxis, protein restriction, purine metabolism, rash/si [Side Effect], recurrent disease/dt [Drug Therapy], recurrent disease/pc [Prevention], risk reduction, side effect/si [Side Effect], sodium restriction, stone dissolution, stone formation/dt [Drug Therapy], stone formation/pc [Prevention], thrombosis/si [Side Effect], ureter stone/dt [Drug Therapy], urolithiasis/dt [Drug Therapy], urolithiasis/th [Therapy], weight reduction, acetohydroxamic acid/ae [Adverse Drug Reaction], acetohydroxamic acid/dt [Drug Therapy], alfuzosin/cm [Drug Comparison], alfuzosin/dt [Drug Therapy], allopurinol/dt [Drug Therapy], alpha adrenergic receptor blocking agent/cm [Drug Comparison], alpha adrenergic receptor blocking agent/dt [Drug Therapy], bicarbonate/dt [Drug Therapy], bicarbonate/po [Oral Drug Administration], calcium/ec [Endogenous Compound], calcium channel blocking agent/dt [Drug Therapy], cellulose phosphate/ae [Adverse Drug Reaction], cellulose phosphate/dt [Drug Therapy], citrate potassium/ae [Adverse Drug Reaction], citrate potassium/cb [Drug Combination], citrate potassium/dt [Drug Therapy], citrate potassium/po [Oral Drug Administration], citric acid/dt [Drug Therapy], corticosteroid/cm [Drug Comparison], corticosteroid/dt [Drug Therapy], deflazacort/cm [Drug Comparison], deflazacort/dt [Drug Therapy], doxazosin/cm [Drug Comparison], doxazosin/dt [Drug Therapy], nifedipine/ct [Clinical Trial], nifedipine/cm [Drug Comparison], nifedipine/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], oxalic acid/ec [Endogenous Compound], penicillamine/ae [Adverse Drug Reaction], penicillamine/cm [Drug Comparison], penicillamine/dt [Drug Therapy], placebo, potassium dihydrogen phosphate/dt [Drug Therapy], scopolamine butyl bromide, tamsulosin/ct [Clinical Trial], tamsulosin/cm [Drug Comparison], tamsulosin/dt [Drug Therapy], terazosin/cm [Drug Comparison], terazosin/dt [Drug Therapy], thiazide diuretic agent/cb [Drug Combination], thiazide diuretic agent/dt [Drug Therapy], tiopronin/ae [Adverse Drug Reaction], tiopronin/cm [Drug Comparison], trometamol/dt [Drug Therapy], uric acid/ec [Endogenous Compound], tiopronin/dt [Drug Therapy], bone pain/si [Side Effect], acid secretion, article, asthenia/si [Side Effect], calcium intake, calcium oxalate stone/dt [Drug Therapy], calcium urine level, cystinuria/dt [Drug Therapy], dermatitis/si [Side Effect], fluid intake, gastrointestinal symptom/si [Side Effect], human, hypercalciuria/dt [Drug Therapy], hypocoagulability/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30184
LibKey Link